Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 1
1998 1
1999 2
2000 1
2001 1
2002 2
2005 1
2007 2
2008 2
2010 2
2011 1
2012 2
2013 1
2014 1
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Simplified versions of the original disease activity score: validation in the BeSt trial.
Koevoets R, Klarenbeek NB, Güler-Yüksel M, van Oosterhout M, van Krugten MV, Kerstens PJ, Huizinga TW, Dijkmans BA, van der Heijde DM, Allaart CF. Koevoets R, et al. Among authors: van krugten mv. Ann Rheum Dis. 2011 Aug;70(8):1471-4. doi: 10.1136/ard.2010.149146. Epub 2011 May 8. Ann Rheum Dis. 2011. PMID: 21551508 Clinical Trial.
Treatment with TNF-α inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis.
Güler-Yüksel M, Allaart CF, Watt I, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Schaardenburg D, van Krugten MV, Dijkmans BA, Huizinga TW, Lems WF, Kloppenburg M. Güler-Yüksel M, et al. Among authors: van krugten mv. Osteoarthritis Cartilage. 2010 Oct;18(10):1256-62. doi: 10.1016/j.joca.2010.07.011. Epub 2010 Aug 5. Osteoarthritis Cartilage. 2010. PMID: 20691795 Free article. Clinical Trial.
TNF-308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus.
Rood MJ, van Krugten MV, Zanelli E, van der Linden MW, Keijsers V, Schreuder GM, Verduyn W, Westendorp RG, de Vries RR, Breedveld FC, Verweij CL, Huizinga TW. Rood MJ, et al. Among authors: van krugten mv. Arthritis Rheum. 2000 Jan;43(1):129-34. doi: 10.1002/1529-0131(200001)43:1<129::AID-ANR16>3.0.CO;2-S. Arthritis Rheum. 2000. PMID: 10643708 Free article.
Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.
Kuijper TM, Luime JJ, de Jong PH, Gerards AH, van Zeben D, Tchetverikov I, de Sonnaville PB, van Krugten MV, Grillet BA, Hazes JM, Weel AE. Kuijper TM, et al. Among authors: van krugten mv. Ann Rheum Dis. 2016 Dec;75(12):2119-2123. doi: 10.1136/annrheumdis-2016-209272. Epub 2016 Jun 9. Ann Rheum Dis. 2016. PMID: 27283332 Clinical Trial.
Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial.
de Jong PH, Hazes JM, Han HK, Huisman M, van Zeben D, van der Lubbe PA, Gerards AH, van Schaeybroeck B, de Sonnaville PB, van Krugten MV, Luime JJ, Weel AE. de Jong PH, et al. Among authors: van krugten mv. Ann Rheum Dis. 2014 Jul;73(7):1331-9. doi: 10.1136/annrheumdis-2013-204788. Epub 2014 May 1. Ann Rheum Dis. 2014. PMID: 24788619 Free PMC article. Clinical Trial.
Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial.
Klarenbeek NB, van der Kooij SM, Huizinga TJ, Goekoop-Ruiterman YP, Hulsmans HM, van Krugten MV, Speyer I, de Vries-Bouwstra JK, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF. Klarenbeek NB, et al. Among authors: van krugten mv. Ann Rheum Dis. 2010 Jul;69(7):1342-5. doi: 10.1136/ard.2009.124180. Epub 2010 May 14. Ann Rheum Dis. 2010. PMID: 20472597 Clinical Trial.
21 results